Quarterly ResultMay 18, 2026, 05:01 PM
NeOnc Q1 Net Loss $8.8M; NEO212 Phase 1 Complete; NEO100 Interim Data Soon
AI Summary
NeOnc Technologies Holdings, Inc. reported a net loss of $8.8 million, or $(0.38) per diluted share, for Q1 2026, a significant improvement from Q1 2025. The company also provided a business update, announcing the successful completion of the Phase 1 dose-escalation for NEO212, setting the recommended Phase 2 dose at 610 mg, and observing early signs of clinical activity. For NEO100, the Phase 2a study in recurrent IDH1-mutant high-grade glioma is fully enrolled with interim data expected in August 2026. Operationally, NeOnc strengthened its balance sheet with a $10 million PIPE financing and appointed David Choi as Chief Accounting Officer.
Key Highlights
- NEO212 Phase 1 completed; Recommended Phase 2 Dose (RP2D) set at 610 mg.
- NEO100 Phase 2a fully enrolled; interim data expected August 2026.
- Q1 2026 Net Loss: $8.8 million, or $(0.38) per diluted share.
- Q1 2026 R&D expenses increased to $1,286,336 from $998,222 YoY.
- Q1 2026 G&A expenses decreased to $488,709 from $849,485 YoY.
- Secured $10 million PIPE financing from Cinctive Capital.
- Cash and cash equivalents as of March 31, 2026: $138,601.
- Maintains a $10 million undrawn line of credit.
Price Impact
More from NTHI